C-Rad AB (publ) - Asset Resilience Ratio
C-Rad AB (publ) (CRAD-B) has an Asset Resilience Ratio of 79.42% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of C-Rad AB (publ) to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how C-Rad AB (publ)'s Asset Resilience Ratio has changed over time. See CRAD-B net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down C-Rad AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see C-Rad AB (publ) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr216.09 Million | 79.42% |
| Total Liquid Assets | Skr216.09 Million | 79.42% |
Asset Resilience Insights
- Very High Liquidity: C-Rad AB (publ) maintains exceptional liquid asset reserves at 79.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
C-Rad AB (publ) Industry Peers by Asset Resilience Ratio
Compare C-Rad AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for C-Rad AB (publ) (2014–2023)
The table below shows the annual Asset Resilience Ratio data for C-Rad AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.01% | Skr-39.00K ≈ $-4.20K |
Skr404.00 Million ≈ $43.48 Million |
+6.82pp |
| 2014-12-31 | -6.83% | Skr-4.96 Million ≈ $-534.23K |
Skr72.66 Million ≈ $7.82 Million |
-- |
About C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more